Robert J. Weinstock, MD; Jonathan Solomon, MD; Cathleen McCabe, MD; and Mitchell A. Jackson, MD, share their thoughts on DEXYCU (EyePoint Pharmaceuticals) postoperatively, as well as data from the Phase 3 Pivotal Trial. This study showed that 10% of patients who received DEXYCU required rescue with a steroid, compared to 50% of patients who received a placebo.
DEXYCU (dexamethasone intraocular suspension) 9% is indicated for the treatment of postoperative inflammation.
DEXYCU is the first and only FDA-approved, single-dose, sustained-release, intracameral steroid for the treatment of postoperative inflammation.1 DEXYCU is injected at the end of cataract surgery and targets the site of inflammation with a clinical effect lasting up to 30 days in most patients.1,2 The primary efficacy endpoint for the clinical study for DEXYCU was the proportion of patients with anterior chamber cell clearing on postoperative day 8. At day 8, the percentage of patients with anterior chamber clearing was significantly lower in the DEXYCU treatment group (60%; n=94/156) compared to the placebo treatment group (20%; n=16/80).1 Here are my tips and tricks on injecting DEXYCU using the capsular bag method after cataract surgery.